Financial Contrast: Corvus Pharmaceuticals (CRVS) versus AC Immune (ACIU)
Corvus Pharmaceuticals (NASDAQ: CRVS) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.
This is a summary of current ratings and price targets for Corvus Pharmaceuticals and AC Immune, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Corvus Pharmaceuticals currently has a consensus price target of $21.67, suggesting a potential upside of 108.53%. AC Immune has a consensus price target of $18.00, suggesting a potential upside of 33.53%. Given Corvus Pharmaceuticals’ higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than AC Immune.
Valuation & Earnings
This table compares Corvus Pharmaceuticals and AC Immune’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corvus Pharmaceuticals||N/A||N/A||-$36.37 million||($2.69)||-3.86|
|AC Immune||$23.55 million||32.58||-$7.20 million||($0.68)||-19.82|
AC Immune has higher revenue and earnings than Corvus Pharmaceuticals. AC Immune is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
83.4% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 17.1% of AC Immune shares are held by institutional investors. 46.4% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Corvus Pharmaceuticals and AC Immune’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
AC Immune beats Corvus Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.